Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher-high trend ⢠Breakout hold ⢠Stretched near resistance Support Level: $253-$254 Resistance Level: $259-$260 ABBV has trended higher over the last month with higher highs/lows and a late-July breakout above $253-$254 to a new high near $259-$260, but it is now stretched near resistance and vulnerable to a short-term pullback.
Sentiment & News
Key News Insights: ⢠Acquisition growth ⢠Post-Humira strength ⢠Valuation debate AbbVie's recent headlines show strong momentum from acquisitions, pipeline growth, and post-Humira products like Skyrizi and Rinvoq, while investors continue to debate whether the stock is still fairly valued despite its dividend appeal.
AI Summary
AbbVie's post-Humira growth story is intact, but with the stock already rerated and margin/EPS conversion weakening under acquisition costs and higher investment, the key takeaway is that ABBV now looks like a solid execution story rather than a cheap one, so upside depends on sustained delivery from Skyrizi/Rinvoq and disciplined capital allocation.
Description
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinsonâs and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 26 | Jul 3 | ABBV | AbbVie Inc. | AbbVie has accelerating defensive healthcare momentum, with Q1 2026 revenue of $15.0B, adjusted EPS up 7.7%, raised full-year 2026 EPS guidance to $14.08-$14.28, FDA approval of DECNUPAZ, filings for SKYRIZI and upadacitinib, clinical data readouts, and about 12.7% price strength over 21 trading days. | Closed | +3.0% |
| Sep 29 | Oct 6 | ABBV | AbbVie Inc. | AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential. | Closed | +3.1% |